Search

Your search keyword '"Laursen, Alex"' showing total 460 results
Start Over Author "Laursen, Alex"
460 results on '"Laursen, Alex"'

1. Safety and efficacy of doravirine as first-line therapy in adults with HIV-1: week 192 results from the open-label extensions of the DRIVE-FORWARD and DRIVE-AHEAD phase 3 trials

Author

Martins, Marcelo D, Cahn, Pedro E, Lopardo, Gustavo D, Porteiro, Norma, Bloch, Mark Theo, Baker, David Alfred, Roth, Norman, Moore, Richard J, Finlayson, Robert James, McMahon, James, Rieger, Armin, Zoufaly, Alexander, Schmied, Brigitte, Hartl, Sylvia, Zangerle, Robert, Smaill, Fiona, Walmsley, Sharon L, Conway, Brian, Rachlis, Anita, Smith, Graham H R, Perez Cortes, Carlos, Afani, Alejandro, Campos Barker, Maria Isabel E, Chahin Anania, Carolina Eugenia, Reyes, Marcelo J. Wolff, Gerstoft, Jan, Weis, Nina, Laursen, Alex Lund, Molina, Jean-Michel, Yazdanpanah, Yazdan, Cotte, Laurent, Raffi, Francois, Slama, Laurence, Morlat, Philippe, Girard, Pierre-Marie, Katlama, Christine, Rockstroh, Juergen K, Arasteh, Keikawus, Esser, Stefan, Stoehr, Albrecht, Stellbrink, Hans-Juergen, Stoll, Matthias, Schuermann, Dirk, Faetkenheuer, Gerd, Bogner, Johannes Richard, Lutz, Thomas, Baumgarten, Axel, Jaeger, Hans, Wiese, Carmen, Gori, Andrea, Migliorino, Guglielmo Marco, Coltan, Gabriel, Constandis, Felicia, Erscoiu, Simona M, Prisacariu, Liviu-Jany, Rugina, Sorin, Streinu-Cercel, Adrian, Pokrovsky, Vadim V, Zakharova, Natalia, Shuldyakov, Andrey Anatolyevich, Ryamova, Elena Pavlovna, Kulagin, Valeriy Viktorovich, Tsybakova, Olga Aleksandrovna, Orlova-Morozova, Elena, Nagimova, Firaya, Voronin, Evgeniy, Shimonova, Tatiana Evgenyevna, Kozyrev, Oleg Anatolyevich, Orrell, Catherine, Lombaard, Johannes Jurgens, Botes, Margaretha Elizabeth, de Jager, Marleen, Segorb, Joaquin Portilla, Gatell Artigas, Josep Maria, Mallolas Masferrer, Josep, Guillen, Santiago Moreno, Perez Elias, Maria Jesus, Arribas Lopez, Jose R, Puigmal, Eugenia Negredo, Podzamczer Palter, Daniel, Ortega, Frederico Pulido, Garcia, Jesus Troya, de los Santos Gil, Ignacio, Berenguer, Juan, Nelson, Mark Richard, Williams, Ian G, Johnson, Margaret A, Khoo, Saye, Schembri, Gabriel, Clarke, Amanda, Gompels, Mark, Fox, Julie Meriel, Lwanga, Julianne, Taylor, Steven John, Dockrell, David Harold, Kegg, Stephen, Hagins, Debbie P, Osiyemi, Olayemi O, Prelutsky, David James, Ramgopal, Moti N, Scarsella, Anthony J, Dretler, Robin, DeJesus, Edwin, Bettacchi, Christopher J, Sims III, James, Clay, Patrick G, Bellos, Nicholaos C, Thompson, Melanie A, Montero, Jose, McDonald, Cheryl K, Creticos, Catherine, Shamblaw, David, Terrelonge, Antonio E, Valdes, Martin, Tashima, Karen T, Robbins, William J, Elion, Richard A, Goldstein, Deborah, Slim, Jihad, Lalezari, Jacob Paul, Pushkin, Richard, Lalla-Reddy, Sujata N, Win, Sanda S, Ruane, Peter Jerome, Mills, Anthony Martin, Cade, Jerry L, Campo, Rafael, Dietz, Craig A, Hoffman-Terry, Margaret, Blick, Gary, Rubin, David Scott, Mayer, Cynthia, Rondon, Juan Carlos, Cook, Paul P, Daar, Eric, Kumar, Princy N, Swindells, Susan, Castro, Jose Guillermo, Morales-Ramirez, Javier O, Santiago, Lizette, Santana-Bagur, Jorge L, Vandekerckhove, Linos, Florence, Eric, De Wit, Stephane, Derdelinckx, Inge, Vandercam, Bernard, Belkhir, Leila, De Wet, Joseph, Lebouche, Bertrand, Trottier, Benoit, Longpre, Daniele, Szabo, Jason, LeBlanc, Roger P, Jensen, Werner, Gonzalez, Alvaro Rojas, Beltran, Carlos, Sussmann, Otto Alberto, Velez, Juan Diego, Onate, Jose Millan, Nielsen, Henrik, Degen, Olaf, Stephan, Christoph, Arathoon, Eduardo, Lopez, Rudy Manuel, Rojas Alvarado, Evelyn Michelle, Gonzalez Patzan, Luis Demetrio, Meija, Carlos R, Pinzon, Rodolfo, Parchment, Charles, Sthoeger, Zev, Chowers, Michal, Riesenberg, Klaris, Shahar, Eduardo, Levy, Itzchak, Quintero Perez, Nora Patricia, Andrade-Villanueva, Jaime Federico, Crabtree Ramirez, Brenda Eloisa, Rijnders, Bart, den Hollander, Jan G, Handy, Rupert, Morales, Nilo Bonifacio, Hidalgo, Jose Alfredo, Infante, Rosa Mercedes, Matos Prado, Eduardo Demetrio, Campos, Pablo E, Ticona Chaves, Eduardo Romulo, Pinedo, Yvett, Pacheco, Patricia, Maltez, Fernando Manuel, Cunha, Jose, Neves, Isabel, Serrao, Rosario, Melendez-Rivera, Ivan, Mendoza-Rodriguez, Rafael O, Maldonado-Rivera, Sandra, Ortiz-Lasanta, Grisell, Kizhlo, Svetlana, Freud, Hernando Knobel, Moreno, Jose Sanz, Mendez, Francisco Vera, Mohapi, Lerato, Mitha, Essack Aziz, Mahomed, Akbar Anvar, Fouche, Leon Frederik, Kaplan, Richard, Siddique, Naeem, Hoosen, Farzana, Rassool, Mohammed Siddique, Baraldi, Ezio, Calmy, Alexandra, Cavassini, Matthias, Fehr, Jan, Tsai, Hung-Chin, Lin, Hsi-Hsun, Huang, Chun-Kai, Ko, Wen-Chien, Lin, Yu-Hui, Chen, Su-Jung, Hung, Chien-Ching, Avihingsanon, Anchalee, Kiertiburanakul, Sasisopin, Ratanasuwan, Winai, Supparatpinyo, Khuanchai, Chetchotisakd, Ploenchan, Changpradub, Dhitiwat, Orkin, Chloe, Fox, Ashini, Winston, Alan, Ustianowski, Andrew, Yangco, Bienvenido G, Asmuth, David Michael, Vigil, Karen J, Berger, Daniel S, Bhatti, Laveeza, Campbell, Thomas, Casey, Kathleen K, Liu, Edward, Crofoot, Gordon E, Cunningham, Douglas, Feinberg, Judith, Fichtenbaum, Carl, Balamban Felizarta, Franco Antonio, Jefferson, Thomas T, Johnson, Marc Alexander, Lewis, Stanley T, Luque, Amneris E, Novak, Richard M, Sloan, Louis, Sweet, Donna E, Towner, William J, Zane, Ryan, Riedel, David J, Loftus, Richard Anton, Shon, Alyssa So Young, Mogyoros, Miguel, Tebas, Pablo, Scott, Mia Louise, Parenti, David M, Inciarte Portillo, Alexy, Cahn, Pedro, Lombaard, Johannes, Kumar, Sushma, Campbell, Havilland, Wan, Hong, Teal, Valerie, Jin Xu, Zhi, Asante-Appiah, Ernest, Sklar, Peter, Teppler, Hedy, and Lahoulou, Rima

Published
2024
Full Text
View/download PDF

3. Dangers of Herpesvirus Infection in SLE Patients Under Anifrolumab Treatment: Case Reports and Clinical Implications.

Author

Larsen, Mads Lamm, Skouboe, Morten Kelder, Mogensen, Trine Hyrup, Laursen, Alex Lund, Deleuran, Bent, Troldborg, Anne, and Bendix Rasch, Mads Nyhuus

Subjects
SYSTEMIC lupus erythematosus, DRUG side effects, HERPESVIRUS diseases, RESPIRATORY infections, HERPES simplex virus, HERPES zoster
Abstract

Background: Anifrolumab, a monoclonal antibody targeting the type 1 interferon (IFN-I) signaling pathway, holds promise as a therapeutic intervention for systemic lupus erythematosus (SLE). However, its use is associated with an increased risk of infections, particularly viral infections like herpes zoster (HZ). Results from the clinical trials on anifrolumab show yearly rates of upper respiratory tract infections of 34% and HZ of 6.1%. An increased frequency of other specific viral infections, including herpes simplex virus (HSV), was not reported. Case Reports: Here, we present 2 cases of patients with SLE treated with anifrolumab, both experiencing severe adverse reactions in the form of disseminated herpesvirus infections, specifically disseminated HSV-2 and varicella zoster virus (VZV, HZ encephalitis). To the best of our knowledge, no previous reports of severe disseminated HSV-2 or HZ have been published in anifrolumab-treated patients. The patient in case 1 experienced a primary HSV-2 infection following anifrolumab treatment, potentially explaining the severity of the infection. The patient in case 2 had a history of previous HZ skin infections, which may have increased her risk of disseminated infection. Both patients recovered from the infections with minor sequelae, but they still require prophylactic antiviral treatment. These cases highlight the critical role of IFN-I immunity in protecting against herpesvirus infections. Conclusions: Thorough risk assessment before anifrolumab initiation, considering the patient's viral infection history, vaccination status, and potential exposure risks, is essential. Administration of recombinant zoster vaccine before anifrolumab therapy may benefit susceptible individuals. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

4. Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial

Author

Hagins, Debbie P., Osiyemi, Olayemi O., Prelutsky, David James, Ramgopal, Moti N., Scarsella, Anthony John, Dretler, Robin, DeJesus, Edwin, Bettacchi, Christopher J., Sims, James, III, Clay, Patrick G., Bellos, Nicholaos C., Thompson, Melanie A., Montero, Jose, McDonald, Cheryl K., Creticos, Catherine, Shamblaw, David, Mogyoros, Miguel, Terrelonge, Antonio E., Valdes, Martin, Tashima, Karen T., Robbins, William J., Felizarta, Franco Antonio, Elion, Richard A., Slim, Jihad, Win, Sandra S., Lalla-Reddy, Sujata N., Ruane, Peter Jerome, Mills, Anthony, Cade, Jerry L., Dietz, Craig A., Rubin, David Scott, Mayer, Cynthia, Rondon, Juan Carlos, Cook, Paul P., Daar, Eric, Kumar, Princy N., Swindells, Susan, Castro, Jose Guillermo, Melendez-Rivera, Ivan, Morales-Ramirez, Javier O., Santiago, Lizette, Santana-Bagur, Jorge L., Martins, Marcelo, Cahn, Pedro Enrique, Lopardo, Gustavo D., Porteiro, Norma, Bloch, Mark Theo, Baker, David Alfred, Roth, Norman, Moore, Richard James, Finlayson, Robert James, McMahon, James, Rieger, Armin, Zoufaly, Alexander, Hartl, Sylvia, Zangerle, Robert, Smaill, Fiona, Walmsley, Sharon L., Conway, Brian, Rachlis, Anita, Smith, Graham H.R., Perez, Carlos, Afani, Alejandro, Campos, Maria Isabel, Chahin, Carolina Eugenia, Wolff Reyes, Marcelo, Gerstoft, Jan, Weis, Nina, Laursen, Alex Lund, Molina, Jean-Michel, Yazdanpanah, Yazdan, Cotte, Laurent, Raffi, Francois, Morlat, Philippe, Girard, Pierre-Marie, Katlama, Christine, Rockstroh, Juergen K., Arasteh, Keikawus, Esser, Stefan, Stoehr, Albrecht, Stellbrink, Hans-Juergen, Stoll, Matthias, Schuermann, Dirk, Faetkenheuer, Gerd, Bogner, Johannes, Lutz, Thomas, Baumgarten, Axel, Jaeger, Hans, Gori, Andrea, Coltan, Gabriel, Constandis, Felicia, Erscoiu, Simona Manuela, Prisacariu, Liviu-Jany, Rugina, Sorin, Streinu-Cercel, Adrian, Pokrovsky, Vadim Valentinovich, Zakharova, Natalia V., Shuldyakov, Andrey Anatolyevich, Ryamova, Elena Pavlovna, Kulagin, Valeriy Viktorovich, Tsybakova, Olga Aleksandrovna, Orlova-Morozova, Elena, Nagimova, Firaya, Voronin, Evgeniy, Shimonova, Tatyana Evgenyevna, Kozyrev, Oleg Anatolyevich, Orrell, Catherine, Lombaard, Johannes Jurgens, de Jager, Marleen, Portilla Segorb, Joaquin, Mallolas, Josep, Perez Elias, Maria Jesus, Gatell, Josep M., Arribas Lopez, Jose Ramon, Negredo Puigmal, Eugenia, Podzamczer Palter, Daniel, Pulido Ortega, Federico, Troya Garcia, Jesus, De los Santos Gil, Ignacio, Berenguer Berenguer, Juan, Williams, Ian G., Johnson, Margaret A., Schembri, Gabriel, Clarke, Amanda, Gompels, Mark, Fox, Julie Meriel, Taylor, Steven John, Dockrell, David Harold, Kegg, Stephen, Squires, Kathleen, Sax, Paul E, Cahn, Pedro, Lombaard, Johan, Lai, Ming-Tain, Rodgers, Anthony, Lupinacci, Lisa, Kumar, Sushma, Sklar, Peter, Hanna, George J, Hwang, Carey, and Martin, Elizabeth Anne

Published
2020
Full Text
View/download PDF

6. Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial

Author

Martins, Marcelo, Cahn, Pedro Enrique, Lopardo, Gustavo D., Porteiro, Norma, Bloch, Mark Theo, Baker, David Alfred, Roth, Norman, Moore, Richard James, Finlayson, Robert James, McMahon, James, Rieger, Armin, Zoufaly, Alexander, Hartl, Sylvia, Zangerle, Robert, Smaill, Fiona, Walmsley, Sharon L., Conway, Brian, Rachlis, Anita, Smith, Graham H.R., Perez, Carlos, Afani, Alejandro, Campos Barker, Maria Isabel E., Chahin, Carolina Eugenia, Wolff Reyes, Marcelo, Gerstoft, Jan, Weis, Nina, Laursen, Alex Lund, Molina, Jean-Michel, Yazdanpanah, Yazdan, Cotte, Laurent, Raffi, Francois, Morlat, Philippe, Girard, Pierre-Marie, Katlama, Christine, Rockstroh, Juergen K., Arasteh, Keikawus, Esser, Stefan, Stoehr, Albrecht, Stellbrink, Hans-Juergen, Stoll, Matthias, Schuermann, Dirk, Faetkenheuer, Gerd, Bogner, Johannes, Lutz, Thomas, Baumgarten, Axel, Jaeger, Hans, Gori, Andrea, Coltan, Gabriel, Constandis, Felicia, Erscoiu, Simona Manuela, Prisacariu, Liviu-Jany, Rugina, Sorin, Streinu-Cercel, Adrian, Pokrovsky, Vadim Valentinovich, Zakharova, Natalia V., Shuldyakov, Andrey Anatolyevich, Ryamova, Elena Pavlovna, Kulagin, Valeriy Viktorovich, Tsybakova, Olga Aleksandrovna, Orlova-Morozova, Elena, Nagimova, Firaya, Voronin, Evgeniy, Shimonova, Tatyana Evgenyevna, Kozyrev, Oleg Anatolyevich, Orrell, Catherine, Lombaard, Johannes Jurgens, Botes, Margaretha Elizabeth, Portilla, Joaquin, Gatell, Josep Maria, Perez, Maria Jesus, Arribas, Jose Ramon, Negredo, Eugenia, Podzamczer, Daniel, Pulido, Federico, Troya, Jesus, De los Santos, Ignacio, Berenguer, Juan, Williams, Ian G., Johnson, Margaret A., Schembri, Gabriel, Clarke, Amanda, Gompels, Mark, Fox, Julie Meriel, Taylor, Steven John, Kegg, Stephen, Hagins, Debbie P., Osiyemi, Olayemi O., Prelutsky, David James, Ramgopal, Moti N., Dretler, Robin, DeJesus, Edwin, Sloan, Louis, Lewis, Stanley T., Clay, Patrick G., Bellos, Nicholaos C., Thompson, Melanie A., Montero, Jose, McDonald, Cheryl K., Creticos, Catherine, Shamblaw, David, Terrelonge, Antonio E., Valdes, Martin, Tashima, Karen T., Robbins, William J., Felizarta, Franco Antonio, Elion, Richard A., Slim, Jihad, Lalezari, Jacob Paul, Lalla-Reddy, Sujata N., Ruane, Peter Jerome, Mills, Anthony, Cade, Jerry L., Campo, Rafael E., Dietz, Craig A., Blick, Gary, Mayer, Cynthia, Rondon, Juan Carlos, Cook, Paul P., Daar, Eric, Kumar, Princy N., Swindells, Susan, Castro, Jose Guillermo, Morales-Ramirez, Javier O., Santiago, Lizette, Santana-Bagur, Jorge L., Squires, Kathleen, Sax, Paul E, Cahn, Pedro, Lombaard, Johan, Lai, Ming-Tain, Xu, Xia, Rodgers, Anthony, Lupinacci, Lisa, Kumar, Sushma, Sklar, Peter, Nguyen, Bach-Yen, Hanna, George J, and Hwang, Carey

Published
2018
Full Text
View/download PDF

7. Safety and efficacy of an 8-week regimen of grazoprevir plus ruzasvir plus uprifosbuvir compared with grazoprevir plus elbasvir plus uprifosbuvir in participants without cirrhosis infected with hepatitis C virus genotypes 1, 2, or 3 (C-CREST-1 and C-CREST-2, part A): two randomised, phase 2, open-label trials

Author

Gane, Edward J, Pianko, Stephen, Roberts, Stuart K, Thompson, Alexander J, Zeuzem, Stefan, Zuckerman, Eli, Ben-Ari, Ziv, Foster, Graham R, Agarwal, Kosh, Laursen, Alex L, Gerstoft, Jan, Gao, Wei, Huang, Hsueh-Cheng, Fitzgerald, Brian, Fernsler, Doreen, Li, Jerry J, Grandhi, Anjana, Liu, Hong, Su, Feng-Hsiu, Wan, Shuyan, Zeng, Zhen, Chen, Huei-Ling, Dutko, Frank J, Nguyen, Bach-Yen T, Wahl, Janice, Robertson, Michael N, Barr, Eliav, Yeh, Wendy W, Plank, Rebeca M, Butterton, Joan R, and Esteban, Rafael

Published
2017
Full Text
View/download PDF

9. Safety and efficacy of doravirine as first-line therapy in adults with HIV-1: week 192 results from the open-label extensions of the DRIVE-FORWARD and DRIVE-AHEAD phase 3 trials

Author

Orkin, Chloe, Molina, Jean-Michel, Cahn, Pedro, Lombaard, Johannes, Supparatpinyo, Khuanchai, Kumar, Sushma, Campbell, Havilland, Wan, Hong, Teal, Valerie, Jin Xu, Zhi, Asante-Appiah, Ernest, Sklar, Peter, Teppler, Hedy, Lahoulou, Rima, Martins, Marcelo D, Cahn, Pedro E, Lopardo, Gustavo D, Porteiro, Norma, Bloch, Mark Theo, Baker, David Alfred, Roth, Norman, Moore, Richard J, Finlayson, Robert James, McMahon, James, Rieger, Armin, Zoufaly, Alexander, Schmied, Brigitte, Hartl, Sylvia, Zangerle, Robert, Smaill, Fiona, Walmsley, Sharon L, Conway, Brian, Rachlis, Anita, Smith, Graham H R, Perez Cortes, Carlos, Afani, Alejandro, Campos Barker, Maria Isabel E, Chahin Anania, Carolina Eugenia, Reyes, Marcelo J. Wolff, Gerstoft, Jan, Weis, Nina, Laursen, Alex Lund, Molina, Jean-Michel, Yazdanpanah, Yazdan, Cotte, Laurent, Raffi, Francois, Slama, Laurence, Morlat, Philippe, Girard, Pierre-Marie, Katlama, Christine, Rockstroh, Juergen K, Arasteh, Keikawus, Esser, Stefan, Stoehr, Albrecht, Stellbrink, Hans-Juergen, Stoll, Matthias, Schuermann, Dirk, Faetkenheuer, Gerd, Bogner, Johannes Richard, Lutz, Thomas, Baumgarten, Axel, Jaeger, Hans, Wiese, Carmen, Gori, Andrea, Migliorino, Guglielmo Marco, Coltan, Gabriel, Constandis, Felicia, Erscoiu, Simona M, Prisacariu, Liviu-Jany, Rugina, Sorin, Streinu-Cercel, Adrian, Pokrovsky, Vadim V, Zakharova, Natalia, Shuldyakov, Andrey Anatolyevich, Ryamova, Elena Pavlovna, Kulagin, Valeriy Viktorovich, Tsybakova, Olga Aleksandrovna, Orlova-Morozova, Elena, Nagimova, Firaya, Voronin, Evgeniy, Shimonova, Tatiana Evgenyevna, Kozyrev, Oleg Anatolyevich, Orrell, Catherine, Lombaard, Johannes Jurgens, Botes, Margaretha Elizabeth, de Jager, Marleen, Segorb, Joaquin Portilla, Gatell Artigas, Josep Maria, Mallolas Masferrer, Josep, Guillen, Santiago Moreno, Perez Elias, Maria Jesus, Arribas Lopez, Jose R, Puigmal, Eugenia Negredo, Podzamczer Palter, Daniel, Ortega, Frederico Pulido, Garcia, Jesus Troya, de los Santos Gil, Ignacio, Berenguer, Juan, Nelson, Mark Richard, Williams, Ian G, Johnson, Margaret A, Khoo, Saye, Schembri, Gabriel, Clarke, Amanda, Gompels, Mark, Fox, Julie Meriel, Lwanga, Julianne, Taylor, Steven John, Dockrell, David Harold, Kegg, Stephen, Hagins, Debbie P, Osiyemi, Olayemi O, Prelutsky, David James, Ramgopal, Moti N, Scarsella, Anthony J, Dretler, Robin, DeJesus, Edwin, Bettacchi, Christopher J, Sims III, James, Clay, Patrick G, Bellos, Nicholaos C, Thompson, Melanie A, Montero, Jose, McDonald, Cheryl K, Creticos, Catherine, Shamblaw, David, Terrelonge, Antonio E, Valdes, Martin, Tashima, Karen T, Robbins, William J, Elion, Richard A, Goldstein, Deborah, Slim, Jihad, Lalezari, Jacob Paul, Pushkin, Richard, Lalla-Reddy, Sujata N, Win, Sanda S, Ruane, Peter Jerome, Mills, Anthony Martin, Cade, Jerry L, Campo, Rafael, Dietz, Craig A, Hoffman-Terry, Margaret, Blick, Gary, Rubin, David Scott, Mayer, Cynthia, Rondon, Juan Carlos, Cook, Paul P, Daar, Eric, Kumar, Princy N, Swindells, Susan, Castro, Jose Guillermo, Morales-Ramirez, Javier O, Santiago, Lizette, Santana-Bagur, Jorge L, Vandekerckhove, Linos, Florence, Eric, De Wit, Stephane, Derdelinckx, Inge, Vandercam, Bernard, Belkhir, Leila, De Wet, Joseph, Lebouche, Bertrand, Trottier, Benoit, Longpre, Daniele, Szabo, Jason, LeBlanc, Roger P, Jensen, Werner, Gonzalez, Alvaro Rojas, Beltran, Carlos, Sussmann, Otto Alberto, Velez, Juan Diego, Onate, Jose Millan, Nielsen, Henrik, Degen, Olaf, Stephan, Christoph, Arathoon, Eduardo, Lopez, Rudy Manuel, Rojas Alvarado, Evelyn Michelle, Gonzalez Patzan, Luis Demetrio, Meija, Carlos R, Pinzon, Rodolfo, Parchment, Charles, Sthoeger, Zev, Chowers, Michal, Riesenberg, Klaris, Shahar, Eduardo, Levy, Itzchak, Quintero Perez, Nora Patricia, Andrade-Villanueva, Jaime Federico, Crabtree Ramirez, Brenda Eloisa, Rijnders, Bart, den Hollander, Jan G, Handy, Rupert, Morales, Nilo Bonifacio, Hidalgo, Jose Alfredo, Infante, Rosa Mercedes, Matos Prado, Eduardo Demetrio, Campos, Pablo E, Ticona Chaves, Eduardo Romulo, Pinedo, Yvett, Pacheco, Patricia, Maltez, Fernando Manuel, Cunha, Jose, Neves, Isabel, Serrao, Rosario, Melendez-Rivera, Ivan, Mendoza-Rodriguez, Rafael O, Maldonado-Rivera, Sandra, Ortiz-Lasanta, Grisell, Kizhlo, Svetlana, Freud, Hernando Knobel, Moreno, Jose Sanz, Mendez, Francisco Vera, Mohapi, Lerato, Mitha, Essack Aziz, Mahomed, Akbar Anvar, Fouche, Leon Frederik, Kaplan, Richard, Siddique, Naeem, Hoosen, Farzana, Rassool, Mohammed Siddique, Baraldi, Ezio, Calmy, Alexandra, Cavassini, Matthias, Fehr, Jan, Tsai, Hung-Chin, Lin, Hsi-Hsun, Huang, Chun-Kai, Ko, Wen-Chien, Lin, Yu-Hui, Chen, Su-Jung, Hung, Chien-Ching, Avihingsanon, Anchalee, Kiertiburanakul, Sasisopin, Ratanasuwan, Winai, Supparatpinyo, Khuanchai, Chetchotisakd, Ploenchan, Changpradub, Dhitiwat, Orkin, Chloe, Fox, Ashini, Winston, Alan, Ustianowski, Andrew, Yangco, Bienvenido G, Asmuth, David Michael, Vigil, Karen J, Berger, Daniel S, Bhatti, Laveeza, Campbell, Thomas, Casey, Kathleen K, Liu, Edward, Crofoot, Gordon E, Cunningham, Douglas, Feinberg, Judith, Fichtenbaum, Carl, Balamban Felizarta, Franco Antonio, Jefferson, Thomas T, Johnson, Marc Alexander, Lewis, Stanley T, Luque, Amneris E, Novak, Richard M, Sloan, Louis, Sweet, Donna E, Towner, William J, Zane, Ryan, Riedel, David J, Loftus, Richard Anton, Shon, Alyssa So Young, Mogyoros, Miguel, Tebas, Pablo, Scott, Mia Louise, Parenti, David M, and Inciarte Portillo, Alexy

Abstract

In two phase 3 trials for first-line therapy in adults with HIV-1, doravirine showed non-inferior efficacy, a favourable safety profile, and a superior lipid profile to darunavir and efavirenz through to 48 and 96 weeks. Here we report 192-week results from both studies.

Published
2024
Full Text
View/download PDF

11. Assessing factors for loss to follow-up of HIV infected patients in Guinea-Bissau

Author

Nordentoft, Pernille Bejer, Engell-Sørensen, Thomas, Jespersen, Sanne, Correia, Faustino Gomes, Medina, Candida, da Silva Té, David, Østergaard, Lars, Laursen, Alex Lund, Wejse, Christian, Hønge, Bo Langhoff, Rodrigues, Amabelia, da Silva, David, da Silva, Zacarias, Medina, Candida, Oliviera-Souto, Ines, Østergaard, Lars, Laursen, Alex, Hønge, Bo, Aaby, Peter, Fomsgaard, Anders, Erikstrup, Christian, Jespersen, Sanne, Wejse, Christian, and Bissau HIV Cohort study group

Published
2017
Full Text
View/download PDF

18. Incidence of Hepatocellular Carcinoma and Decompensated Liver Cirrhosis and Prognostic Accuracy of the PAGE-B HCC Risk Score in a Low Endemic Hepatitis B Virus Infected Population

Author

Bollerup, Signe, primary, Engsig, Frederik, additional, Hallager, Sofie, additional, Mocroft, Amanda, additional, Roege, Birgit T, additional, Christensen, Peer B, additional, Laursen, Alex L, additional, Krarup, Henrik, additional, Clausen, Mette R, additional, Thielsen, Peter, additional, Madsen, Lone G, additional, Noerregaard, Lars, additional, Barfod, Toke S, additional, Balslev, Ulla, additional, Tarp, Britta, additional, Hansen, Jesper B, additional, Mygind, Lone H, additional, Gerstoft, Jan, additional, and Weis, Nina, additional

Published
2022
Full Text
View/download PDF

19. Ischemic Heart Disease in Chronic Hepatitis B: A Danish Nationwide Cohort Study

Author

Lau, Frederik Faergemann, primary, Bollerup, Signe, additional, Engsig, Frederik, additional, Krarup, Henrik, additional, Mygind, Lone Hagens, additional, Hansen, Jesper Bach, additional, Madsen, Lone Galmstrup, additional, Thielsen, Peter, additional, Balslev, Ulla, additional, Nielsen, Lars Nørregaard, additional, Barfod, Toke S, additional, Clausen, Mette Rye, additional, Hobolth, Lise, additional, Laursen, Alex Lund, additional, Tarp, Britta, additional, Roege, Birgit T, additional, Gerstoft, Jan, additional, Christensen, Peer Brehm, additional, and Weis, Nina, additional

Published
2022
Full Text
View/download PDF

20. Grazoprevir, ruzasvir, and uprifosbuvir for hepatitis C virus after NS5A treatment failure

Author

Wyles, David, Wedemeyer, Heiner, Ben‐Ari, Ziv, Gane, Edward J., Hansen, Jesper Bach, Jacobson, Ira M., Laursen, Alex L., Luetkemeyer, Annie, Nahass, Ronald, Pianko, Stephen, Zeuzem, Stefan, Jumes, Patricia, Huang, Hsueh‐Cheng, Butterton, Joan, Robertson, Michael, Wahl, Janice, Barr, Eliav, Joeng, Hee‐Koung, Martin, Elizabeth, and Serfaty, Lawrence

Published
2017
Full Text
View/download PDF

21. Ischemic Heart Disease in Chronic Hepatitis B: A Danish Nationwide Cohort Study

Author

Lau,Frederik Faergemann, Bollerup,Signe, Engsig,Frederik, Krarup,Henrik, Mygind,Lone Hagens, Hansen,Jesper Bach, Madsen,Lone Galmstrup, Thielsen,Peter, Balslev,Ulla, Nielsen,Lars Nørregaard, Barfod,Toke S, Clausen,Mette Rye, Hobolth,Lise, Laursen,Alex Lund, Tarp,Britta, Roege,Birgit T, Gerstoft,Jan, Christensen,Peer Brehm, Weis,Nina, Lau,Frederik Faergemann, Bollerup,Signe, Engsig,Frederik, Krarup,Henrik, Mygind,Lone Hagens, Hansen,Jesper Bach, Madsen,Lone Galmstrup, Thielsen,Peter, Balslev,Ulla, Nielsen,Lars Nørregaard, Barfod,Toke S, Clausen,Mette Rye, Hobolth,Lise, Laursen,Alex Lund, Tarp,Britta, Roege,Birgit T, Gerstoft,Jan, Christensen,Peer Brehm, and Weis,Nina

Abstract

Frederik Faergemann Lau,1 Signe Bollerup,1 Frederik Engsig,1 Henrik Krarup,2 Lone Hagens Mygind,3 Jesper Bach Hansen,3 Lone Galmstrup Madsen,4,5 Peter Thielsen,6 Ulla Balslev,7 Lars Nørregaard Nielsen,8 Toke S Barfod,9 Mette Rye Clausen,10 Lise Hobolth,11 Alex Lund Laursen,12 Britta Tarp,13 Birgit T Roege,14 Jan Gerstoft,15 Peer Brehm Christensen,16,17 Nina Weis1,5 1Department of Infectious Diseases, Copenhagen University Hospital-Hvidovre, Hvidovre, Denmark; 2Department of Molecular Diagnostics, Aalborg University Hospital, Aalborg, Denmark; 3Department of Medical Gastroenterology, Aalborg University Hospital, Aalborg, Denmark; 4Department of Medical Gastroenterology, Zealand University Hospital, Koege, Denmark; 5Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; 6Department of Gastroenterology, Copenhagen University Hospital-Herlev, Herlev, Denmark; 7Department of Infectious Diseases, Copenhagen University Hospital-Herlev, Herlev, Denmark; 8Department of Lung- and Infectious Diseases, North Zealand Hospital-Hilleroed, Hilleroed, Denmark; 9Department of Internal Medicine and Infectious Diseases, Zealand University Hospital, Roskilde, Denmark; 10Department of Medical Gastroenterology and Hepatology, Copenhagen University Hospital-Rigshospitalet, Copenhagen, Denmark; 11Department of Gastroenterology, Copenhagen University Hospital-Hvidovre, Hvidovre, Denmark; 12Department of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark; 13Diagnostic Center, Silkeborg Regional Hospital, Silkeborg, Denmark; 14Department of Internal Medicine, Kolding Hospital, Kolding, Denmark; 15Department of Infectious Diseases, Copenhagen University Hospital-Rigshospitalet, Copenhagen, Denmark; 16Department of Infectious Diseases, Odense University Hospital, Odense, Denmark; 17Clinical Institute, University of Southern Denmark, Odense, DenmarkCorrespondence: Nina Weis, Department of Infectious Diseases, Copenhag

Published
2022

22. Mortality and cause of death in persons with chronic hepatitis B virus infection versus healthy persons from the general population in Denmark

Author

Bollerup, Signe, Hallager, Sofie, Engsig, Frederik, Mocroft, Amanda, Krarup, Henrik, Madsen, Lone G., Thielsen, Peter, Balslev, Ulla, Mens, Helene, Barfod, Toke S., Clausen, Mette R., Hobolth, Lise, Laursen, Alex L., Tarp, Britta, Roege, Birgit T., Hansen, Jesper B., Mygind, Lone, Christensen, Peer B., Gerstoft, Jan, Weis, Nina, Bollerup, Signe, Hallager, Sofie, Engsig, Frederik, Mocroft, Amanda, Krarup, Henrik, Madsen, Lone G., Thielsen, Peter, Balslev, Ulla, Mens, Helene, Barfod, Toke S., Clausen, Mette R., Hobolth, Lise, Laursen, Alex L., Tarp, Britta, Roege, Birgit T., Hansen, Jesper B., Mygind, Lone, Christensen, Peer B., Gerstoft, Jan, and Weis, Nina

Abstract

The study aimed to determine adjusted all-cause mortality and cause of death in persons with chronic hepatitis B virus (HBV) infection compared with age- and sex-matched persons from the general population. We used nationwide registers to identify persons aged >= 18 years with chronic HBV infection in 2002-2017 in Denmark and included 10 age- and sex-matched controls for each. Follow-up was from 6 months after diagnosis until death, emigration, or 31 December 2017. Mortality rate ratios (MRRs) adjusted for age, sex, employment, origin and comorbidity were calculated using Poisson regression. Unadjusted cause-specific mortality rate ratios with 95% confidence intervals were calculated assuming a Poisson distribution. A total of 6988 persons with chronic HBV infection and 69,847 controls were included. During a median follow-up of 7.7 years (range 0.0-15.5), 315 (5%) persons with-and 1525 (2%) without-chronic HBV infection died. The adjusted all-cause MRR was 1.5 (95% CI 1.2-2.0). Persons with chronic HBV infection had increased mortality due to liver disease including hepatocellular carcinoma (MRR 12.3 [8.6-17.7]), external causes (MRR 3.3 [2.5-4.7]), endocrine disease (MRR 3.2 [1.8-5.4]), genitourinary disease (MRR 3.2 [1.2-7.6]) and neoplasms (except hepatocellular carcinoma; MRR 1.6 [1.2-2.0]). In conclusion, this study showed an increased all-cause mortality in persons with chronic HBV infection in comparison with age- and sex-matched persons without chronic HBV infection which remained after adjustment for several confounding factors. Excess mortality was mainly associated with liver disease, but also external factors, endocrine disease, genitourinary disease and neoplasms (excluding hepatocellular carcinoma).

Published
2022

23. Ischemic Heart Disease in Chronic Hepatitis B:A Danish Nationwide Cohort Study

Author

Lau, Frederik Faergemann, Bollerup, Signe, Engsig, Frederik, Krarup, Henrik, Mygind, Lone Hagens, Hansen, Jesper Bach, Madsen, Lone Galmstrup, Thielsen, Peter, Balslev, Ulla, Nielsen, Lars Nørregaard, Barfod, Toke S., Clausen, Mette Rye, Hobolth, Lise, Laursen, Alex Lund, Tarp, Britta, Roege, Birgit T., Gerstoft, Jan, Christensen, Peer Brehm, Weis, Nina, Lau, Frederik Faergemann, Bollerup, Signe, Engsig, Frederik, Krarup, Henrik, Mygind, Lone Hagens, Hansen, Jesper Bach, Madsen, Lone Galmstrup, Thielsen, Peter, Balslev, Ulla, Nielsen, Lars Nørregaard, Barfod, Toke S., Clausen, Mette Rye, Hobolth, Lise, Laursen, Alex Lund, Tarp, Britta, Roege, Birgit T., Gerstoft, Jan, Christensen, Peer Brehm, and Weis, Nina

Abstract

Objective: Data on the risk of ischemic heart disease (IHD) in patients with chronic hepatitis B virus (CHB) are conflicting. Our objective was to address the rate of IHD in patients with CHB compared with individuals without CHB (control-persons) from the general population. Study Design and Setting: We conducted a cohort study of prospectively obtained data from Danish nationwide registries. We produced cumulative incidence curves and calculated the unadjusted incidence rate ratio (IRR) of IHD in persons with and without CHB. The adjusted association between having CHB and developing IHD was examined using a cause-specific Cox regression model. Results: In total, 6472 persons with CHB and 62,251 age-and sex-matched individuals from the general population were followed for 48,840 and 567,456 person-years, respectively, during which 103 (1,59%) with CHB and 1058 (1,70%) control-persons developed IHD. The crude IRR was 1.13 (95% CI: 0.91–1.39). CHB did not have a statistically significant effect on the rate of IHD after adjusting for several confounding factors (adjusted hazard ratio: 0.96, 95% CI: 0.76–1.21). Conclusion: In this nationwide cohort study, we did not find any difference between rate of IHD in persons with CHB in comparison with the general population.

Published
2022

24. Incidence of Hepatocellular Carcinoma and Decompensated Liver Cirrhosis and Prognostic Accuracy of the PAGE-B HCC Risk Score in a Low Endemic Hepatitis B Virus Infected Population

Author

Bollerup, Signe, Engsig, Frederik, Hallager, Sofie, Mocroft, Amanda, Roege, Birgit T., Christensen, Peer B., Laursen, Alex L., Krarup, Henrik, Clausen, Mette R., Thielsen, Peter, Madsen, Lone G., Noerregaard, Lars, Barfod, Toke S., Balslev, Ulla, Tarp, Britta, Hansen, Jesper B., Mygind, Lone H., Gerstoft, Jan, Weis, Nina, Bollerup, Signe, Engsig, Frederik, Hallager, Sofie, Mocroft, Amanda, Roege, Birgit T., Christensen, Peer B., Laursen, Alex L., Krarup, Henrik, Clausen, Mette R., Thielsen, Peter, Madsen, Lone G., Noerregaard, Lars, Barfod, Toke S., Balslev, Ulla, Tarp, Britta, Hansen, Jesper B., Mygind, Lone H., Gerstoft, Jan, and Weis, Nina

Abstract

Purpose: We aimed to determine incidence of hepatocellular carcinoma (HCC) and decompensated liver cirrhosis in persons with chronic hepatitis B virus (HBV) infection in Denmark stratified by disease phase, liver cirrhosis, and treatment status at baseline. Additionally, we aimed to assess the prognostic value of the PAGE-B HCC risk score in a mainly non-cirrhotic population. Patients and Methods: In this register-based cohort study, we included all individuals over the age of 18, with chronic HBV infection first registered between 2002 and 2016 in at least one of three nationwide registers. The study population was followed until HCC, decompensated liver cirrhosis, death, emigration, or December 31, 2017, which ever came first. Results: Among 6016 individuals included in the study, 10 individuals with and 23 without baseline liver cirrhosis developed HCC during a median follow up of 7.3 years (range 0.0-15.5). This corresponded to five-year cumulative incidences of 7.1% (95% confidence interval (CI) 2.0-12.3) and 0.2% (95% CI 0.1-0.4) in persons with and without baseline liver cirrhosis. The five-year cumulative incidence of decompensated liver cirrhosis was 0.7% (95% CI 0.5-1.0). Among 2038 evaluated for liver events stratified by disease phase, incidence of HCC was low in all who were non-cirrhotic and untreated for HBV at baseline. PAGE-B score was evaluated in 1529 persons. The 5-year cumulative incidence of HCC was 0, 0.8 (95% CI 0.5-1.8), and 8.7 (95% CI 1.0-16.4) in persons scoring 17, respectively (c-statistic 0.91 (95% CI 0.84-0.98)). Conclusion: We found low incidence of HCC and decompensated liver cirrhosis in persons with chronic HBV infection in Denmark. Moreover, the PAGE-B score showed good accuracy for five-year risk of developing HCC in the population with chronic HBV infection in Denmark.

Published
2022

25. Mortality and cause of death in persons with chronic hepatitis B virus infection versus healthy persons from the general population in Denmark

Author

Bollerup, Signe, primary, Hallager, Sofie, additional, Engsig, Frederik, additional, Mocroft, Amanda, additional, Krarup, Henrik, additional, Madsen, Lone G., additional, Thielsen, Peter, additional, Balslev, Ulla, additional, Mens, Helene, additional, Barfod, Toke S., additional, Clausen, Mette R., additional, Hobolth, Lise, additional, Laursen, Alex L., additional, Tarp, Britta, additional, Roege, Birgit T., additional, Hansen, Jesper B., additional, Mygind, Lone, additional, Christensen, Peer B., additional, Gerstoft, Jan, additional, and Weis, Nina, additional

Published
2022
Full Text
View/download PDF

26. Diabetes mellitus and impaired fasting glucose in ART-naïve patients with HIV-1, HIV-2 and HIV-1/2 dual infection in Guinea-Bissau: a cross-sectional study

Author

Steiniche, Ditte, Jespersen, Sanne, Erikstrup, Christian, Krarup, Henrik, Handberg, Aase, Østergaard, Lars, Haraldsdottir, Thorny, Medina, Candida, Gomes Correira, Faustino, Laursen, Alex Lund, Bjerregaard-Andersen, Morten, Wejse, Christian, Hønge, Bo Langhoff, Rodrigues, Amabelia, da Silva, David, da Silva, Zacarias, Medina, Candida, Oliviera-Souto, Ines, Østergaard, Lars, Laursen, Alex, Jespersen, Sanne, Aaby, Peter, Fomsgaard, Anders, Erikstrup, Christian, Langhoff Hønge, Bo, and Wejse, Christian

Published
2016
Full Text
View/download PDF

27. Differential effects of sex in a West African cohort of HIV-1, HIV-2 and HIV-1/2 dually infected patients: men are worse off

Author

Jespersen, Sanne, Hnge, Bo Langhoff, Esbjörnsson, Joakim, Medina, Candida, da Silva Té, David, Correira, Faustino Gomes, Laursen, Alex Lund, stergaard, Lars, Andersen, Andreas, Aaby, Peter, Erikstrup, Christian, Wejse, Christian, Rodrigues, Amabelia, da Silva, David, da Silva, Zacarias, Oliviera-Souto, Ines, Laursen, Alex, Sodemann, Morten, Fomsgaard, Anders, and Eugen-Olsen, Jesper

Published
2016
Full Text
View/download PDF

28. Challenges facing HIV treatment in Guinea-Bissau: the benefits of international research collaborations/Defis a relever pour le traitement du VIH en Guinee-Bissau: les avantages des collaborations en matiere de recherche internationale/Los desafios que afronta el tratamiento del VIH en Guinea-Bissau: los beneficios de las colaboraciones en la investigacion internacional

Author

Jespersen, Sanne, Honge, Bo Langhoff, Oliveira, Ines, Medina, Candida, Te, David da Silva, Correia, Faustino Gomes, da Silva, Zacarias Jose, Erikstrup, Christian, Ostergaard, Lars, Laursen, Alex Lund, and Wejse, Christian

Subjects
HIV infections -- Care and treatment, Cooperative research -- International aspects, Health
Abstract

Problem The introduction of antiretroviral therapy (ART) for HIV infection in sub-Saharan Africa has improved the quality of life of millions of people and reduced mortality. However, substantial problems with the infrastructure for ART delivery remain. Approach Clinicians and researchers at an HIV clinic in Guinea-Bissau identified problems with the delivery of ART by establishing a clinical database and by collaborating with international researchers. Local setting The Bissau HIV cohort study group was established in 2007 as a collaboration between local HIV physicians and international HIV researchers. Patients were recruited from the HIV clinic at the country's main hospital in the capital Bissau. Relevant changes Between 2005 and 2013, 5514 HIV-positive patients were treated at the clinic. Working together, local health-care workers and international researchers identified the main problems affecting ART delivery: inadequate drug supply; loss of patients to follow-up; and inadequate laboratory services. Solutions to these problems were devised. The collaborations encouraged local physicians to start their own research projects to find possible solutions to problems at the clinic. Lessons learnt The HIV clinic in Bissau faced numerous obstacles in delivering ART at a sufficiently high quality and patients' lives were put in jeopardy. The effectiveness of ART could be enhanced by delivering it as part of an International research collaboration since such collaborations can help identify problems, find solutions and increase the capacity of the health-care system. Probleme L'introduction de la therapie antiretrovirale (TAR) pourtraiter la contamination par le VIH en Afrique subsaharienne a ameliore la qualite de vie de millions de personnes et redult la mortalite. Cependant, l'infrastructure de distribution de la TAR reste tres problematique. Approche Les cliniciens et les chercheurs d'une clinique de Guinee Bissau ont identifie des problemes avec la distribution de la IAK en creant une base de donnees clinique et en collaborant avec des chercheurs internatlonaux. Environnement local Le groupe d'etude de la cohorte VIH de Bissau a ete cree en 2007 comme une collaboration entre des medecins locaux traitant le VIH et des chercheurs internationaux etudlant le VIH. Les patients ont ete recrutesa la clinique VIH situee dans l'hopital principal du pays a Bissau, la capitale. Changements significatifs Entre 2005 et 2013, 5514 patients seropositifs ont ete traites a la clinique. En travaillant ensemble, les personnels de sante locaux et les chercheurs internationaux ont identifie les problemes principaux qui affectaient la distribution de la TAR: un approvisionnement inapproprie des medicaments; des patients perdus de vue et des services de laboratoire inadequats. Des solutions visant a resoudre ces problemes ont ete envisagees. Les collaborations ont encourage les medecins locaux a lancer leurs propres projets de recherche afin de trouver des solutions possibles aux problemes rencontres a la clinique. Lecons tirees La clinique VIH de Bissau a du faire face a de nombreux obstacles pour distrlbuer une TAR d'une qualite suffisamment elevee, et les vies des patients ont ete mises en peril. Lefficacite de la TAR pourrait etre augmentee en la distribuant dans le cadre de collaborations de recherche Internationale, puisque ces collaborations peuvent aider a identifier les problemes, a trouver des solutions et a augmenter la capacite du systeme de sante. Situacion La introduccion de la terapia antirretroviral (TARV) para tratar la Infeccion del VIH en el Africa subsahariana ha mejorado la calidad de vida de millones de personas y ha reducido la mortalidad. No obstante, siguen existiendo problemas considerables relacionados con la infraestructura para el suministro de la terapia antirretroviral. Enfoque En una clinica del VIH de Guinea-Bissau, los medicos y los investigadores detectaron problemas en el suministro de la terapia antirretroviral mediante la creacion de una base de datos y la colaboracion con investigadores internacionales. Marco regional El grupo del estudio de cohorte para el VIH de Bissau se creo en 2007, fruto de la colaboracion entre los medicos del VIH locales y los Investigadores del VIH Internacionales. Se selecciono a los pacientes de la clinica de VIH en el hospital principal del pais de la capital Bissau. Cambios importantes Entre 2005 y 2013, se trato a 5514 pacientes seropositivos para el VIH en la clinica. Trabajando en equipo, el personal sanitario local y los investigadores internacionales Identificaron los problemas principales que repercuten en el suministro de la terapia antirretroviral: el suministro inadecuado de medicamentos; la perdida de pacientes durante el seguimiento y los servicios de laboratorio inadecuados. Se disenaron soluciones para estos problemas. Las colaboraciones animaron a los medicos locales a emprender sus propios proyectos de investigacion a fin de hallar soluciones a los problemas en la clinica. Lecciones aprendidas La clinica del VIH de Bissau afronto diversos obstaculos en el suministro de una terapia antirretroviral de calidad suficientemente alta y se pusieron en riesgo las vidas de los pacientes. Es posible aumentar la eficacia de la terapia antirretroviral si esta se suministra como parte de la colaboracion de una investigacion internacional, ya que este tipo de colaboraciones pueden ayudar a Identificar los problemas, hallar soluciones y aumentar la capacidad del sistema sanitario., Introduction In sub-Saharan Africa, the introduction of antiretroviral therapy (ART) for patients with human immunodeficiency virus (HIV) infections has improved the lives of millions of people and decreased mortality. (1) [...]

Published
2014
Full Text
View/download PDF

30. Reply to Focosi

Author

Engsig, Frederik Neess, Hansen, Ann-Brit Eg, Omland, Lars Haukali, Kronborg, Gitte, Gerstoft, Jan, Laursen, Alex Lund, Pedersen, Court, Mogensen, Christian Backer, Nielsen, Lars, and Obel, Niels

Published
2009
Full Text
View/download PDF

32. Discriminatory rapid tests cause HIV-type misclassification—evaluation of three rapid tests using clinical samples from Guinea-Bissau

Author

Hønge, Bo Langhoff, Jespersen, Sanne, Medina, Candida, Té, David Da Silva, Da Silva, Zacarias José, Christiansen, Mette, Kjerulff, Bertram, Laursen, Alex Lund, Wejse, Christian, Krarup, Henrik, Erikstrup, Christian, Rodrigues, Amabelia, Da Silva, David, Oliviera-Souto, Ines, Østergaard, Lars, Aaby, Peter, and Fomsgaard, Anders

Subjects
0301 basic medicine, medicine.medical_specialty, Human immunodeficiency virus (HIV), First Response, medicine.disease_cause, Treatment failure, 03 medical and health sciences, Reference test, Genie III, 0302 clinical medicine, Internal medicine, medicine, Guinea-Bissau, Bioline, 030212 general & internal medicine, INFECTED PATIENTS, business.industry, Public Health, Environmental and Occupational Health, HIV type, virus diseases, General Medicine, 030112 virology, Alternative treatment, Dna detection, Infectious Diseases, Guinea bissau, HIV-2, Cohort, Parasitology, business
Abstract

BackgroundDiscrimination among HIV types is important because HIV-2 is naturally resistant to some of the first-line drugs used in the treatment of HIV-1. We evaluated three assays for HIV-type discriminatory capacity: SD Bioline HIV 1/2 3.0 (Bioline), First Response HIV 1-2-0 Card Test (First Response) and Genie III HIV-1/HIV-2 (Genie III).MethodsBased on results from the Bioline assay, samples from 239 HIV-infected patients from the Bissau HIV cohort in Guinea-Bissau were retrospectively selected for evaluation. Genie III and First Response were scored by three independent readers and compared with a reference test (INNO-LIA HIV I/II Score) confirmed by HIV RNA as well as DNA detection.ResultsThe best performing test was Genie III, with an average agreement with the reference test of 93.4%, followed by First Response (86.1%) and Bioline (72.4%). First Response and Bioline were scored with a false high number of HIV-1/2 dual infections. For both First Response and Genie III, there were discrepancies among independent readers, and some tests were scored as HIV non-reactive.ConclusionsUsing these rapid tests with a suboptimal performance will presumably result in a high rate of false HIV-1/2 dual diagnoses, depriving patients of alternative treatment options in cases of treatment failure.

Published
2019

34. Global evolutionary analysis of chronic hepatitis C patients revealed significant effect of baseline viral resistance, including novel non-target sites, for DAA-based treatment and retreatment outcome

Author

Fahnøe, Ulrik, Pedersen, Martin S., Sølund, Christina, Ernst, Anja, Krarup, Henrik B., Røge, Birgit T., Christensen, Peer B., Laursen, Alex L., Gerstoft, Jan, Thielsen, Peter, Madsen, Lone G., Pedersen, Anders G., Schønning, Kristian, Weis, Nina, Bukh, Jens, Fahnøe, Ulrik, Pedersen, Martin S., Sølund, Christina, Ernst, Anja, Krarup, Henrik B., Røge, Birgit T., Christensen, Peer B., Laursen, Alex L., Gerstoft, Jan, Thielsen, Peter, Madsen, Lone G., Pedersen, Anders G., Schønning, Kristian, Weis, Nina, and Bukh, Jens

Abstract

Direct-acting antivirals (DAAs) have proven highly effective against chronic hepatitis C virus (HCV) infection. However, some patients experience treatment failure, associated with resistance-associated substitutions (RASs). Our aim was to investigate the complete viral coding sequence in hepatitis C patients treated with DAAs to identify RASs and the effects of treatment on the viral population. We selected 22 HCV patients with sustained virologic response (SVR) to match 21 treatment-failure patients in relation to HCV genotype, DAA regimen, liver cirrhosis and previous treatment experience. Viral-titre data were compared between the two patient groups, and HCV full-length open reading frame deep-sequencing was performed. The proportion of HCV NS5A-RASs at baseline was higher in treatment-failure (82%) than matched SVR patients (25%) (p =.0063). Also, treatment failure was associated with slower declines in viraemia titres. Viral population diversity did not differ at baseline between SVR and treatment-failure patients, but failure was associated with decreased diversity probably caused by selection for RAS. The NS5B-substitution 150V was associated with sofosbuvir treatment failure in genotype 3a. Further, mutations identified in NS2, NS3-helicase and NS5A-domain-III were associated with DAA treatment failure in genotype 1a patients. Six retreated HCV patients (35%) experienced 2nd treatment failure; RASs were present in 67% compared to 11% with SVR. In conclusion, baseline RASs to NS5A inhibitors, but not virus population diversity, and lower viral titre decline predicted HCV treatment failure. Mutations outside of the DAA targets can be associated with DAA treatment failure. Successful DAA retreatment in patients with treatment failure was hampered by previously selected RASs.

Published
2021

35. Life expectancy of HIV-infected patients followed at the largest hospital in Guinea-Bissau is one-fourth of life expectancy of the background population

Author

Engell-Sørensen, Thomas, Rieckmann, Andreas, Medina, Candida, da Silva Té, David, Rodrigues, Amabelia, Fisker, Ane Bærent, Aaby, Peter, Erikstrup, Christian, Jespersen, Sanne, Wejse, Christian, Hønge, Bo Langhoff, da Silva, Zacarias, Oliviera-Souto, Ines, Østergaard, Lars, Laursen, Alex, Fomsgaard, Anders, Engell-Sørensen, Thomas, Rieckmann, Andreas, Medina, Candida, da Silva Té, David, Rodrigues, Amabelia, Fisker, Ane Bærent, Aaby, Peter, Erikstrup, Christian, Jespersen, Sanne, Wejse, Christian, Hønge, Bo Langhoff, da Silva, Zacarias, Oliviera-Souto, Ines, Østergaard, Lars, Laursen, Alex, and Fomsgaard, Anders

Abstract

Purpose: To estimate the life expectancy (LE) of HIV-infected patients in the West African country Guinea-Bissau and compare it with the background population. Methods: Using data from the largest HIV outpatient clinic at the Hospital Nacional Simão Mendes in the capital Bissau, a retrospective observational cohort study was performed. The study included patients attending the clinic between June 2005 and January 2018. A total of 8958 HIV-infected patients were included. In the analysis of the background population, a total of 109,191 people were included. LE incorporating loss to follow-up (LTFU) was estimated via Kaplan–Meier estimators using observational data on adult HIV-infected patients and background population. Results: The LE of 20-year-old HIV-infected patients was 9.8 years (95% CI 8.3–11.5), corresponding to 22.3% (95% CI 18.5–26.7%) of the LE of the background population. (LE for 20-year-olds in the background population was 44.0 years [95% CI 43.0–44.9].) Patients diagnosed with CD4 cell counts below 200 cells/µL had a LE of 5.7 years (95% CI 3.6–8.2). No increase in LE with later calendar period of diagnosis was observed. Conclusions: LE was shown to be markedly lower among HIV-infected patients compared with the background population. While other settings have shown marked improvements in prognosis of HIV-infected patients in recent years, no improvement in Bissau was observed over time (9.8 years (95% CI 7.6–12.2) and 9.9 years (95% CI 7.6–12.1) for the periods 2005–2010 and 2014–2016, respectively).

Published
2021

36. Elimination af hepatitis C-virus i Danmark

Author

Døssing, Anna, Røge, Birgit Thorup, Madsen, Lone Galmstrup, Laursen, Alex Lund, Hansen, Jesper Bach, Bukh, Jens, and Weis, Nina

Subjects
virus diseases
Abstract

In Denmark, about 50% of patients with chronic hepatitis C virus (HCV) infection are undiagnosed. Since 2014, therapy containing direct-acting antivirals (DAA) has proven efficient and is available to all patients, who have a chronic HCV infection and a Danish personal identification number. The World Health Organization has a goal of elimination of viral hepatitis in 2030. Elimination of HCV in Denmark should focus on reducing HCV transmission, incidence and prevalence, combined with treatment with DAA of all infected patients. Micro-elimination strategies may play a major role, but a national strategy is lacking.

Published
2020

37. Impact of Hepatitis C virus coinfection on response to highly active antiretroviral therapy and outcome in HIV-infected individuals: a nationwide cohort study

Author

Weis, Nina, Lindhardt, Bjarne O., Kronborg, Gitte, Hansen, Ann-Brit E., Laursen, Alex L., Christensen, Peer B., Nielsen, Henrik, Moller, Axel, Sorensen, Henrik T., and Obel, Niels

Subjects
Hepatitis C virus -- Research, Hepatitis C virus -- Physiological aspects, HIV patients -- Research, Antiviral agents -- Research, Antiviral agents -- Physiological aspects, Health, Health care industry
Published
2006

38. Global evolutionary analysis of chronic hepatitis C patients revealed significant effect of baseline viral resistance, including novel non‐target sites, for DAA‐based treatment and retreatment outcome

Author

Fahnøe, Ulrik, primary, Pedersen, Martin S., additional, Sølund, Christina, additional, Ernst, Anja, additional, Krarup, Henrik B., additional, Røge, Birgit T., additional, Christensen, Peer B., additional, Laursen, Alex L., additional, Gerstoft, Jan, additional, Thielsen, Peter, additional, Madsen, Lone G., additional, Pedersen, Anders G., additional, Schønning, Kristian, additional, Weis, Nina, additional, and Bukh, Jens, additional

Published
2020
Full Text
View/download PDF

39. Altered balance between collagen formation and degradation after successful direct‐acting antiviral therapy of chronic hepatitis C

Author

Laursen, Tea Lund, primary, Villesen, Ida Falk, additional, Leeming, Diana Julie, additional, Karsdal, Morten Asser, additional, Sølund, Christina, additional, Tarp, Britta, additional, Kristensen, Lena Hagelskjær, additional, Holmboe, Charlotte Henneberg, additional, Leutscher, Peter, additional, Laursen, Alex Lund, additional, Gudmann, Natasja Stæhr, additional, and Grønbæk, Henning, additional

Published
2020
Full Text
View/download PDF

41. Influence of baseline resistance on treatment outcome in patients treated for chronic hepatitis C in Denmark: a nationwide study

Author

Fahnøe, Ulrik, primary, Pedersen, Martin Schou, additional, Sølund, Christina, additional, Hallager, Sofie, additional, Ernst, Anja, additional, Krarup, Henrik, additional, Røge, Birgit Thorup, additional, Christensen, Peer Brehm, additional, Laursen, Alex, additional, Gerstoft, Jan, additional, Thielsen, Peter, additional, Madsen, Lone, additional, Pedersen, Anders Gorm, additional, Schønning, Kristian, additional, Weis, Nina, additional, and Bukh, Jens, additional

Published
2020
Full Text
View/download PDF

43. Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial

Author

Molina, Jean-Michel, primary, Squires, Kathleen, additional, Sax, Paul E, additional, Cahn, Pedro, additional, Lombaard, Johan, additional, DeJesus, Edwin, additional, Lai, Ming-Tain, additional, Rodgers, Anthony, additional, Lupinacci, Lisa, additional, Kumar, Sushma, additional, Sklar, Peter, additional, Hanna, George J, additional, Hwang, Carey, additional, Martin, Elizabeth Anne, additional, Hagins, Debbie P., additional, Osiyemi, Olayemi O., additional, Prelutsky, David James, additional, Ramgopal, Moti N., additional, Scarsella, Anthony John, additional, Dretler, Robin, additional, Bettacchi, Christopher J., additional, Sims, James, additional, Clay, Patrick G., additional, Bellos, Nicholaos C., additional, Thompson, Melanie A., additional, Montero, Jose, additional, McDonald, Cheryl K., additional, Creticos, Catherine, additional, Shamblaw, David, additional, Mogyoros, Miguel, additional, Terrelonge, Antonio E., additional, Valdes, Martin, additional, Tashima, Karen T., additional, Robbins, William J., additional, Felizarta, Franco Antonio, additional, Elion, Richard A., additional, Slim, Jihad, additional, Win, Sandra S., additional, Lalla-Reddy, Sujata N., additional, Ruane, Peter Jerome, additional, Mills, Anthony, additional, Cade, Jerry L., additional, Dietz, Craig A., additional, Rubin, David Scott, additional, Mayer, Cynthia, additional, Rondon, Juan Carlos, additional, Cook, Paul P., additional, Daar, Eric, additional, Kumar, Princy N., additional, Swindells, Susan, additional, Castro, Jose Guillermo, additional, Melendez-Rivera, Ivan, additional, Morales-Ramirez, Javier O., additional, Santiago, Lizette, additional, Santana-Bagur, Jorge L., additional, Martins, Marcelo, additional, Cahn, Pedro Enrique, additional, Lopardo, Gustavo D., additional, Porteiro, Norma, additional, Bloch, Mark Theo, additional, Baker, David Alfred, additional, Roth, Norman, additional, Moore, Richard James, additional, Finlayson, Robert James, additional, McMahon, James, additional, Rieger, Armin, additional, Zoufaly, Alexander, additional, Hartl, Sylvia, additional, Zangerle, Robert, additional, Smaill, Fiona, additional, Walmsley, Sharon L., additional, Conway, Brian, additional, Rachlis, Anita, additional, Smith, Graham H.R., additional, Perez, Carlos, additional, Afani, Alejandro, additional, Campos, Maria Isabel, additional, Chahin, Carolina Eugenia, additional, Wolff Reyes, Marcelo, additional, Gerstoft, Jan, additional, Weis, Nina, additional, Laursen, Alex Lund, additional, Molina, Jean-Michel, additional, Yazdanpanah, Yazdan, additional, Cotte, Laurent, additional, Raffi, Francois, additional, Morlat, Philippe, additional, Girard, Pierre-Marie, additional, Katlama, Christine, additional, Rockstroh, Juergen K., additional, Arasteh, Keikawus, additional, Esser, Stefan, additional, Stoehr, Albrecht, additional, Stellbrink, Hans-Juergen, additional, Stoll, Matthias, additional, Schuermann, Dirk, additional, Faetkenheuer, Gerd, additional, Bogner, Johannes, additional, Lutz, Thomas, additional, Baumgarten, Axel, additional, Jaeger, Hans, additional, Gori, Andrea, additional, Coltan, Gabriel, additional, Constandis, Felicia, additional, Erscoiu, Simona Manuela, additional, Prisacariu, Liviu-Jany, additional, Rugina, Sorin, additional, Streinu-Cercel, Adrian, additional, Pokrovsky, Vadim Valentinovich, additional, Zakharova, Natalia V., additional, Shuldyakov, Andrey Anatolyevich, additional, Ryamova, Elena Pavlovna, additional, Kulagin, Valeriy Viktorovich, additional, Tsybakova, Olga Aleksandrovna, additional, Orlova-Morozova, Elena, additional, Nagimova, Firaya, additional, Voronin, Evgeniy, additional, Shimonova, Tatyana Evgenyevna, additional, Kozyrev, Oleg Anatolyevich, additional, Orrell, Catherine, additional, Lombaard, Johannes Jurgens, additional, de Jager, Marleen, additional, Portilla Segorb, Joaquin, additional, Mallolas, Josep, additional, Perez Elias, Maria Jesus, additional, Gatell, Josep M., additional, Arribas Lopez, Jose Ramon, additional, Negredo Puigmal, Eugenia, additional, Podzamczer Palter, Daniel, additional, Pulido Ortega, Federico, additional, Troya Garcia, Jesus, additional, De los Santos Gil, Ignacio, additional, Berenguer Berenguer, Juan, additional, Williams, Ian G., additional, Johnson, Margaret A., additional, Schembri, Gabriel, additional, Clarke, Amanda, additional, Gompels, Mark, additional, Fox, Julie Meriel, additional, Taylor, Steven John, additional, Dockrell, David Harold, additional, and Kegg, Stephen, additional

Published
2020
Full Text
View/download PDF

46. Time‐dependent improvement of liver inflammation, fibrosis and metabolic liver function after successful direct‐acting antiviral therapy of chronic hepatitis C

Author

Laursen, Tea Lund, primary, Siggaard, Cecilie Brøckner, additional, Kazankov, Konstantin, additional, Sandahl, Thomas Damgaard, additional, Møller, Holger Jon, additional, Tarp, Britta, additional, Kristensen, Lena Hagelskjær, additional, Laursen, Alex Lund, additional, Leutscher, Peter, additional, and Grønbæk, Henning, additional

Published
2019
Full Text
View/download PDF

48. Acceptance and Feasibility of Partner Notification to HIV Infected Individuals in Guinea-Bissau.

Author

Madsen, Tina, Jespersen, Sanne, Medina, Candida, Té, David D. S., Wejse, Christian, Laursen, Alex L., Hønge, Bo L., for the Bissau HIV Cohort Study Group, Rodrigues, Amabelia, da Silva Té, David, da Silva, Zacarias, Oliviera-Souto, Ines, Østergaard, Lars, Laursen, Alex Lund, Aaby, Peter, Fomsgaard, Anders, Erikstrup, Christian, and Hønge, Bo Langhoff

Subjects
HIV prevention, HIV-positive persons, CONTACT tracing, SEXUAL partners, CD4 lymphocyte count
Abstract

As partner notification (PN) has shown effective in increasing the number of partners of HIV infected patients being tested we aimed to evaluate the feasibility of implementing PN in the West-African country Guinea-Bissau. Patients enrolled were offered the choice of three different PN methods. Acceptance, successful referrals and HIV status of partners were evaluated. Of 697 patients offered PN, 495 (71.0%) accepted and listed 547 partners. At end of follow-up 118 (21.5%) partners had been tested of which 44 (37.3%) were HIV infected. HIV infected partners had a higher median CD4 count at diagnosis compared with index patients; 401 cells/mm3 versus 240 cells/mm3, p < 0.001. The results indicate that implementation of PN is feasible, effective in identifying HIV infected partners and enables initiation of earlier treatment, yet there are major barriers to bringing partners in for testing which should be addressed in order to exploit the full potential of PN. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results